92 completed, 62 recruiting, 36 unknown, 30 not yet recruiting. 83 Phase 2, 50 Phase 3, 35 Not applicable, 32 Phase 4, 23 Phase 1.
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions Obinutuzumab Beta - Primary IgA Nephropathy | Phase 4 | Not yet recruiting | Ruijin Hospital | 20 | 2026-12-10 | 2026-10-22 |
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy | Phase 2 | Not yet recruiting | Biogen | 25 | 2026-11-16 | 2026-10-22 |
| A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | argenx | 120 | 2026-11-05 | 2026-10-27 |
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-10-30 | 2026-10-15 |
| A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy | Phase 3 | Not yet recruiting | Vertex Pharmaceuticals Incorporated | 40 | 2026-10-23 | 2026-10-22 |
| IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN) | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 100 | 2026-10-15 | 2026-10-21 |
| Mediators of Loin Pain in IgA Nephropathy IgA Nephropathy (IgAN) | Enrolling by invitation | University of Leicester | 40 | 2026-10-13 | 2026-10-20 | |
| A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants Budesonide delayed release tablet - IgA Nephropathy | Phase 1 | Not yet recruiting | Triastek, lnc. | 18 | 2026-10-01 | 2026-10-27 |
| Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN) atrasentan - IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN) | Phase 4 | Not yet recruiting | University of Illinois at Chicago | 20 | 2026-09-29 | 2026-09-21 |
| A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy Povetacicept - Immunoglobulin A Nephropathy | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 605 | 2026-09-17 | 2026-10-19 |
| Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy | Phase 2 | Not yet recruiting | Shaheed Suhrawardy Medical College and Hospital | 104 | 2026-09-01 | 2026-08-25 |
| Universal STAR-T Cell Injection in Autoimmune Kidney Diseases Universal STAR-T Cell - IgA Nephropathy (IgAN), Primary Membranous Nephropathy | Not applicable | Not yet recruiting | Guangdong Provincial People's Hospital | 24 | 2026-08-31 | 2026-08-10 |
| To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies Gd-IgA1 monitoring - IgA Nephropathy (IgAN), Henoch Schönlein Purpura Nephritis | Not applicable | Recruiting | Hong Zhang | 374 | 2026-08-24 | 2026-09-16 |
| Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) QLS7305 Injection - IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-08-10 | 2026-07-28 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-10-15 |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy HRS-5965 Capsules - Primary IgA Nephropathy | Phase 2 | Recruiting | Chengdu Suncadia Medicine Co., Ltd. | 380 | 2026-07-06 | 2026-07-22 |
Showing 20 of 269. Sign in to see all of them.
Proteinuria (38) · Kidney Diseases (29) · Glomerulonephritis (26) · Renal Insufficiency, Chronic (23) · Glomerulonephritis, Membranous (18) · Glomerulosclerosis, Focal Segmental (17) · Diabetic Nephropathies (14) · Autoimmune Diseases (12) · Nephrosis, Lipoid (12) · Lupus Nephritis (11) · Urologic Diseases (11) · Nephrotic Syndrome (9) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (7) · Immune System Diseases (7)
Female Urogenital Diseases (268) · Female Urogenital Diseases and Pregnancy Complications (268) · Male Urogenital Diseases (268) · Urogenital Diseases (264) · Immune System Diseases (262) · Nephritis (262) · Urologic Diseases (258) · Autoimmune Diseases (257) · Glomerulonephritis (243) · Kidney Diseases (240) · Pathological Conditions, Signs and Symptoms (71) · Signs and Symptoms (44) · Pathologic Processes (42) · Urination Disorders (40) · Urological Manifestations (39)
Prednisone (14) · Mycophenolic Acid (13) · Prednisolone (11) · Atrasentan (8) · telitacicept (8) · Adrenal Cortex Hormones (6) · Angiotensin-Converting Enzyme Inhibitors (6) · Losartan (6) · Methylprednisolone (6) · sparsentan (6) · Cyclophosphamide (5) · TACI receptor-IgG Fc fragment fusion protein (5) · iptacopan (5) · Blood Specimen Collection (4) · Budesonide (4)
Novartis Pharmaceuticals (18) · Guangdong Provincial People's Hospital (7) · Sun Yat-sen University (7) · Otsuka Pharmaceutical Development & Commercialization, Inc. (6) · Alexion Pharmaceuticals, Inc. (5) · Calliditas Therapeutics AB (5) · Peking University First Hospital (5) · Ruijin Hospital (5) · The Children's Hospital of Zhejiang University School of Medicine (5) · Travere Therapeutics, Inc. (5) · Centre Hospitalier Universitaire de Saint Etienne (4) · Chengdu Suncadia Medicine Co., Ltd. (4) · Vera Therapeutics, Inc. (4) · Air Force Military Medical University, China (3) · Assistance Publique - Hôpitaux de Paris (3)
China (123) · United States (71) · South Korea (40) · United Kingdom (38) · Australia (34) · Spain (32) · France (30) · Germany (29) · Italy (27) · Taiwan (27) · Canada (22) · Japan (22) · Hong Kong (21) · Malaysia (20) · Argentina (19)
Jicheng Lv (3) · Radko Komers, MD, PhD (3) · Connie L Davis, MD (2) · Eric Michael, MD (2) · Hong Zhang (2) · Jingyuan Xie (2) · Xueqing Yu, MD (2) · Zongpei Jiang, M.D. & Ph.D. (2) · Ahmed Boumediene, doctor (1)
PMID 38299639, PMID 38864363, PMID 26032537, PMID 26630142, PMID 37772889, PMID 28763548, PMID 40465397, PMID 10093981, PMID 18930568, PMID 28341274, PMID 35675911, PMID 37254256, PMID 37528520, PMID 38724717, PMID 39331470, PMID 39455063, PMID 39899371, PMID 40482854, PMID 40938675, PMID 41442197, PMID 42275148, PMID 42384439, PMID 10676716, PMID 11877568, PMID 14694168, PMID 15851648, PMID 16014059, PMID 17533019, PMID 17699247, PMID 17978307, PMID 18436082, PMID 18587715, PMID 19571790, PMID 19571791, PMID 19628647, PMID 20843592, PMID 21606384, PMID 21680850, PMID 21852672, PMID 22075320, PMID 22722778, PMID 22995802, PMID 23675422, PMID 23782179, PMID 23787555, PMID 23977072, PMID 24009220, PMID 24029421, PMID 24191893, PMID 24641955
2018 (3), 2023 (3), 2014 (2), 2016 (2), 2017 (2), 2005 (1), 2015 (1), 2019 (1), 2025 (1), K23DK093556 (1), R01DK049368 (1)